SCHEMBL27034845

SCHEMBL27034845

CC(C)(C)OC(=O)N1CC(N2Cc3ccc([N+](=O)[O-])cc3C2)C1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.50
LMNA P02545 1/20 0.50
MAPT P10636 1/20 0.50
ESR2 Q92731 1/20 0.46
DRD2 P14416 1/20 0.45
NR1H2 P55055 1/20 0.45
DPP7 Q9UHL4 1/20 0.43
NAMPT P43490 2/20 0.42
HDAC1 Q13547 1/20 0.41
DDB1 Q16531 1/20 0.41
CRBN Q96SW2 1/20 0.41
GABRA1 P14867 1/20 0.41
GABRG2 P18507 1/20 0.41
GABRB3 P28472 1/20 0.41
GABRA5 P31644 1/20 0.41
GABRA3 P34903 1/20 0.41
GABRA2 P47869 1/20 0.41
GABRA6 Q16445 1/20 0.41
MMP8 P22894 2/20 0.39
MMP3 P08254 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31591055 1.00 ALDH1A1 (0.50) ALDH1A1LMNAMAPTESR2DRD2
SCHEMBL29113466 0.91 ESR2 (0.53) ALDH1A1LMNAMAPTESR2DRD2
SCHEMBL1393643 0.87 ALDH1A1 (0.57) ALDH1A1LMNAMAPTESR2DRD2
SCHEMBL30130812 0.81 NR1H2 (0.67) ALDH1A1LMNAMAPTESR2DRD2
SCHEMBL20045530 0.81 USP30 (0.47) ESR2NR1H2DPP7NAMPTHDAC1
SCHEMBL6499027 0.81 ESR2 (0.69) ALDH1A1LMNAMAPTESR2DRD2
SCHEMBL396485 0.81 NR1H2 (0.67) ALDH1A1LMNAMAPTESR2DRD2
SCHEMBL2731653 0.80 ALDH1A1 (0.59) ALDH1A1LMNAMAPTESR2DRD2
SCHEMBL4674208 0.79 NR1H2 (0.58) ALDH1A1LMNAMAPTESR2DRD2
SCHEMBL25370697 0.78 ALDH1A1 (0.54) ALDH1A1LMNAMAPTMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250235456-A1 METHODS OF USE FOR AZA-QUINAZOLINE COMPOUNDS IAMBIC THERAPEUTICS, INC. 2025-07-24 US disclosed
EP-4558502-A1 AZA-QUINAZOLINE COMPOUNDS AND METHODS OF USE Iambic Therapeutics, Inc. (US) 2025-05-28 EP disclosed
US-20240034731-A1 AZA-QUINAZOLINE COMPOUNDS AND METHODS OF USE IAMBIC THERAPEUTICS, INC. 2024-02-01 US disclosed
WO-2024020419-A1 AZA-QUINAZOLINE COMPOUNDS AND METHODS OF USE IAMBIC THERAPEUTICS, INC. (US) 2024-01-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240034731-A1 AZA-QUINAZOLINE COMPOUNDS AND METHODS OF USE CCNI, CDKN1A, CDK8 ALDH1A1 307/4885LMNA 2911/4885MAPT 3990/4885
US-20250235456-A1 METHODS OF USE FOR AZA-QUINAZOLINE COMPOUNDS AZI2, TPMT, HDAC10 ALDH1A1 713/4885LMNA 2164/4885MAPT 4100/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.